Beta-blockers in Traumatic Brain Injury

Airton Leonardo de Oliveira Manoel1, Sandro Rizoli2, Ayman El-Menyar3, Ruben Peralta4, Hassan Al-Thani5

ABSTRACT

Severe traumatic brain injury (TBI) is a major public health issue, responsible for high rates of long-term disability and mortality. Although severe TBI is a leading cause of death worldwide, even mild head injuries can adversely impact the functional outcome. It is well described that trauma produces a complex stress response to reestablishing homeostasis. The activation of the stress response (i.e., the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system) leads to the release of glucocorticoids and catecholamines. Although fundamental for survival, the stress response is one of the major players in the development of posttraumatic complications. TBI in particular leads to a fast and intense sympathetic nervous system’s activation with huge liberation of both central and peripheral catecholamines, including epinephrine (Epi) and norepinephrine (NE). Since catecholamine levels increase exponentially after TBI, they have been appraised as possible prognostic biomarkers and a target for intervention in this clinical setting. Currently, there is no particular pharmacological treatment available to reduce or limit the progression of secondary brain injury after TBI. However, preliminary data on the use of β-blockers after TBI have shown promising results. A recent meta-analysis estimated an in-hospital mortality reduction of 65%, while a matched case–control study described that the exposure to a β-blocker were associated with improved functional outcome. Despite these promising and interesting results, the use of β-blockage in the acute phase of TBI remains experimental, requiring further evaluation in a well-designed multicenter randomized clinical trial.

Keywords: Beta-blockers, Catecholamines, Prognosis, Traumatic brain injury.

Panamerican Journal of Trauma, Critical Care & Emergency Surgery (2019): 10.5005/jp-journals-10030-1241

INTRODUCTION

The catecholamines acts as outcome markers in an isolated TBI study (the COMA-TBI study)1 have described in a prospective multicenter cohort that TBI patients demonstrated a characteristic pattern of catecholamine release into the peripheral blood over the first 24 hours of injury, which is depicted by a substantial release of Epi and NE in the moments following the trauma (Fig. 1). Patients demonstrated a large peak of catecholamine levels on hospital admission followed by a continuous decrease thereafter.

It is well described that TBI leads to instantaneous and intense activation of sympathetic nervous system with a huge release of both central and peripheral catecholamines.1,2 This adaptive phenomenon is fundamental for survival, as a single episode of systolic blood pressure (SBP) below 90 mm Hg doubles mortality.3 Recently, additional information emerged showing that blood pressure threshold associated with outcome is even higher after TBI.4 The brain trauma foundation, therefore, changed its recommendations to "maintaining SBP at ≥100 mm Hg for patients 50–69 years old or at ≥110 mm Hg or above for patients 15–49 or over 70 years old may be considered to decrease mortality and..."
improve outcomes. These recommendations were revised from previous guidelines due to new evidence arising from a large class II retrospective cohort of moderate to severe TBI patients, which included almost 16,000 patients. Patients were grouped into three age groups as mentioned above, and the results suggested that a cutoff of SBP <110 mm Hg should be considered as hypotension in moderate to severe TBI population. These results are corroborated by other studies, which also support the decision of the Brain Trauma Foundation to change the hypotension thresholds.

On the contrary, sympathetic nervous system overactivation, through the release of catecholamine and stimulation of α and β adrenoreceptors, might produce hypermetabolism, protein catabolism, muscle wasting, and increase cardiac and cerebral metabolic rate of oxygen. Additionally, several studies showed a significant association between high catecholamine levels and worse clinical outcomes, such as longer duration of mechanical ventilation and hospital stay, increased myocardial damage, endocrine abnormalities, and unfavorable long-term functional outcome.

In an effort to counterbalance the catecholamine surge, several observational studies have shown that β-blockage may improve outcome. However, these results require further evaluation in a well-designed multicenter randomized clinical trial. Therefore, this article provides a comprehensive review on the association between catecholamines and the pathophysiology of secondary brain injury after TBI, as well as the potential role of β-blockage after severe TBI.

**Search Strategy**

A systematic review using MEDLINE, EMBASE, and Google Scholar was performed from inception to April 30, 2019. Eligible articles that described the association between catecholamine levels and outcome, as articles that tested the use of β-blockers after TBI were searched. The terms “traumatic brain injury” (All Fields) AND “catecholamine” (All Fields) returned 62 articles. Additionally, three recent meta-analyses in this topic were analyzed and their reference lists were scrutinized. Also, the authors own article database was used to retrieve additional articles.

**Early Sympathetic Hyperactivity and the Effects within and outside the Brain**

Systemic complications after TBI are common and affect negatively overall outcome, increasing the rates of morbidity and mortality. Zygun et al. described the effects of neurological complications in a cohort of severe TBI. Out of 209 consecutive patients included in the study, 185 (89%) developed at least one non-neurologic organ dysfunction. The respiratory system was the most common system affected (23%), followed by the cardiovascular system (18%), and the coagulation (4%). The effect of one and two organ failures was significantly associated with mortality (i.e., 40% and 47%, respectively). These systemic complications may result from direct effect of acute brain injury or as a side effect of therapy employed to optimize cerebral blood flow or to treat increased intracranial pressure.

The massive catecholamine surge is one of the main theories implicated in the development of cerebral and systemic complications, which includes changes in the brain itself, and non-neurological organ failures, including the heart, the lungs, the immune, and coagulation systems (Table 1).

**Table 1: System affected by the sympathetic hyperactivity after TBI**

| Effect | Description |
|--------|-------------|
| Heart  | Patients with acute brain injury commonly present cardiac changes, varying from sinus tachycardia to acute ST segment changes and fatal ventricular arrhythmias. A HsTnT (HsTnT) ≥26.5 ng/L predicts all-causes of mortality. Takotsubo cardiomyopathy, a severe form of acute heart failure, occurs in some cases and is mainly due to the massive catecholamine release rather than acute coronary syndrome. |
| Lungs  | The lungs are the most commonly affected organ after TBI. Catecholamine-induced pulmonary vasoconstriction increases the pulmonary hydrostatic pressure and the capillaries permeability, which ultimately leads to the accumulation of fluid into the alveoli (i.e., neurogenic pulmonary edema). |
| Immune | TBI is commonly accompanied by the development of a prominent SIRS, and subsequent anti-inflammatory response in an attempt to counterbalance the progress of SIRS. These processes may lead to some degree of immunosuppression, and, consequently, the development of multiple organ failure, and high rates of death. |
| Coagulation | The development of acute coagulopathy in the context of isolated TBI is associated with high rates of mortality. High catecholamine levels are correlated with endotheilopathy and coagulopathy biomarkers (i.e., procoagulant and hyperfibrinolytic state), which are also associated with unfavorable functional outcome in this case scenario. |
the microcirculation, which, in turn, may lead to ischemia and may worsen the traumatic cerebral edema.

**Heart**

Patients with acute brain injury commonly present acute electrocardiographic (ECG) changes, varying from sinus tachycardia to acute ST segment changes and fatal ventricular arrhythmias\(^{14,25}\). Most of the ECG changes are asymptomatic; however, the evidence of myocardial damage is frequently evidenced by elevated biomarker levels, such as troponin\(^{19,20}\). Ayman El-Menyar et al.\(^{21}\) showed in a large cohort of 490 intubated TBI patients that high-sensitivity troponin T (hsTnT) is an independent predictor of outcome. A hsTnT ≥26.5 ng/L predicted all-causes of mortality (AUC 0.75, 95% CI 0.699–0.801—80% sensitivity). Also, patients with a positive hsTnT had a lower Glasgow Coma Scale and were more likely to experience intraventricular hemorrhage and cerebral edema. In some cases, patients may develop a severe form of acute cardiac failure called the Takotsubo cardiomyopathy. This acute form of heart failure is mainly secondary to myocytolysis with band necrosis, induced by the massive catecholamine release rather than the acute coronary syndrome.\(^{22}\) Interestingly, some studies demonstrated a mortality reduction by the use of β-blocker in the group of TBI patients with elevated troponin levels.\(^{19,20}\)

**Lungs**

Lungs are also frequently involved after acute brain injury. The most common pathologies are pneumonia, neurogenic pulmonary edema, pulmonary embolism, and acute respiratory distress syndrome (ARDS). Catecholamine-induced pulmonary vasoconstriction increases the pulmonary hydrostatic pressure and the capillaries permeability, which ultimately leads to the accumulation of fluid into the alveoli (neurogenic pulmonary edema).\(^{23}\) This process is also perpetuated by inflammatory mechanisms that are also dependent on catecholamine release.\(^{24}\) NE and neurepptide Y that are co-stored in the vesicles in the sympathetic nerve terminations are massively released in the lungs in response to a sympathetic activation. Both mediators play a fundamental role in the genesis of neurogenic pulmonary edema in this clinical scenario, due to their vasoconstrictive activity and by the worsening in the pulmonary vascular permeability.\(^{25,26}\) Holland et al. investigated the influence of respiratory failure on outcome after isolated TBI. The authors included 137 mechanically ventilated patients, of whom 31% developed acute lung injury (ALI) as defined by the old definition by the American-European consensus conference. Mortality in the ALI group (currently defined as mild ARDS) was more than double compared with the group of patients without respiratory failure (38% vs 15%). Additionally, the development of ALI was significantly associated with unfavorable functional outcome according to the Glasgow outcome scale.\(^{26}\)

**Immune System**

The immune system is also activated by catecholamine release after TBI. Dysregulated inflammation may play an important role in the development of non-neurological organ failure after brain injury.\(^{27}\) Increased levels of cytokine in the cerebral spinal fluid (CSF) have been found after TBI,\(^{28}\) and it appears that these cytokines are delivered into the systemic circulation.\(^{29}\) TBI is commonly accompanied by the development of a prominent systemic inflammatory response syndrome (SIRS).\(^{30}\) The inflammatory response may trigger the acute development of acute organ and tissue dysfunction. In a vicious cycle, inflammation leads to acute organ and tissue damage, which in turn triggers the release of more inflammatory biomarkers. Therefore, the acute brain injury produces local and systemic inflammation, with subsequent anti-inflammatory response in an attempt to counterbalance the progress of SIRS. Although the compensatory anti-inflammatory response syndrome is fundamental, it may also induce some degree of immunosuppression, and, consequently, the development of additional organ failure.

**Coagulation System**

The development of coagulopathy is common after multisystem trauma, but patients may develop acute coagulopathy even in the context of isolated TBI, which is associated with high rates of mortality.\(^{31}\) It has been described that high catecholamine levels are correlated with endotheliopathy and coagulopathy biomarkers (procoagulant and hyperfibrinolytic state), which are also associated with unfavorable functional outcome.\(^{24}\)

**ARE β-BLOCKERS PROTECTIVE AFTER TBI?**

Because increased catecholamine levels play a pivotal role in the progression of secondary brain injury, and it is also associated with the development of systemic complications, after TBI, the use of β-blockers in this scenario has been postulated for decades. Experimental models of propranolol administration, a nonspecific β-blocker that crosses the BBB, have been shown in a dose-dependent fashion to improve cerebral perfusion and glucose metabolism, while decreasing cerebral hypoxia. Additionally, β-blockage interrupts the β-adrenergic signaling pathway, which decreases the oxidative and inflammatory stresses, increasing vasodilation, and reducing the heart remodeling. In humans, several meta-analyses, which included mainly observational studies, revealed that the use of β-blockers after TBI is associated with significant lower mortality rates.\(^{32}\)

**Biological Plausibility—The COMA TBI Study**

The COMA-TBI study was a multicenter prospective study that evaluated the association between peripheral catecholamine levels and functional outcome after moderate to severe blunt TBI. A total of 174 patients were included in three-level 1 trauma centers across North America. Patients had their peripheral blood collected to measure Epi and NE levels at admission (baseline) and every 6 hours thereafter in the first 24 hours post-injury. The study demonstrated that raised peripheral catecholamine levels on hospital admission, especially Epi, were independently associated with unfavorable functional outcome (extended Glasgow Outcome Scale (GOSE) 5–8) and mortality after isolated TBI.\(^1\) Patients displayed a characteristic pattern of catecholamine release into the peripheral blood over the first 24 hours of injury, which was depicted by a substantial release in the moments following the trauma (i.e., a large peak of catecholamine levels on hospital admission) followed by a gradual decrease thereafter (Fig. 1). These catecholamine levels were consistently higher in the TBI patients when compared to healthy volunteers.\(^1\) More importantly, elevated catecholamine levels on hospital admission were independently associated with unfavorable long-term functional outcome (Fig. 2). These findings add biological plausibility to the possible benefit of β-blockage after TBI.
Relation between High Catecholamine Levels and Worse Outcomes after TBI

TBI patients are commonly found to display signs of increased sympathetic nervous system activity, such as hypertension and tachycardia. Likewise, some studies showed that exogenous administration of NE rises the consumption of oxygen, and also increases the respiratory rate, lactic acid production, and blood glucose.

There are several mechanisms that may be implicated in the complex interaction between the sympathoadrenal activation and the brain, which may explain the unfavorable outcome after TBI (Table 2):

- Epi injection during cardiopulmonary resuscitation has deleterious consequences on cerebral microvascular blood flow because it decreases cortical microcirculatory blood flow, which worsens the intensity of cerebral ischemia during cardiopulmonary resuscitation, and also after the return of spontaneous circulation.
- Sympathoadrenal activation mediates the systemic inflammatory response, and the development of coagulopathy and endotheliopathy. Endothelial damage/dysfunction, mostly glyocalyx disruption resulted from sympathoadrenal activation, is the main driver of coagulopathy and endotheliopathy in this clinical scenario.
- High circulating catecholamine levels are independently associated with these biomarkers of inflammation, endotheliopathy, and coagulopathy in the first 24 hours after brain injury. These biomarkers of coagulopathy and endotheliopathy are associated with unfavorable outcome in isolated TBI patients.
- Increased cardiac demand—the heart can be negatively affected through different mechanisms after acute brain injury, as described above in the section “Early Sympathetic Hyperactivity and the Effects within and outside the Brain”
- Hypermetabolism, protein catabolism, and muscle wasting—in other clinical scenarios associated with sympathoadrenergic overactivation, such as multiple trauma and severe burn, increased sympathoadrenergic system activity is associated with hypermetabolism, altered lipid, and protein metabolism, which cause muscle wasting and loss of lean body mass.
- Augmented intracapillary hydrostatic pressure and the development of vasogenic cerebral edema—this topic will be further discussed in the Lund Protocol section.

Table 2: Why sympathoadrenal over activation may lead to unfavorable outcome after TBI?

| (a) | Reduction in the cerebral microvascular blood flow
| (b) | Induction of systemic inflammatory response
| (c) | Development of coagulopathy/endotheliopathy
| (d) | Increased cardiac demand
| (e) | Hypermetabolism, protein catabolism, and muscle wasting
| (f) | Development of vasogenic cerebral edema

**Association between β-blockers Use and Outcome**

We performed a systematic review using MEDLINE, EMBASE, and Google Scholar. Eligible articles that tested the use of β-blockers after TBI were searched. Only one complete randomized clinical trial was found. The authors randomized 114 hemodynamically stable patients (intervention: 56, control: 58) to receive atenolol (10 mg intravenously four times a day for 7 days) vs placebo. Nineteen patients (30%) in the placebo group vs two patients (7.4%) in the atenolol group displayed myocardial isoenzyme of creatine kinase (CKMB) levels greater than 3% of total creatine kinase (CK), which is compatible with acute myocardial infarction. No patient in the atenolol group vs 16.7% of patients in the placebo group had CKMB levels greater than 6% of total CK, which may be compatible with acute myocardial infarction. Therefore, the use of atenolol was associated with lower likelihood of cardiac events, such as supraventricular tachycardia or ST-segment changes; however, the study was not powered to detect differences in mortality.

Another single-center randomized clinical trial tested the adrenergic blockade by the use of propranolol (1 mg intravenously every 6 hours for 7 days) + clonidine (0.1 mg per tube every 12 hours for 7 days), started within 48 hours post-injury vs placebo. The recruitment has been completed, but the study results have not yet been published. According to the results exhibited in the website of ClinicalTrials.gov (Trial Registration: NCT01322048), patients randomized to adrenergic blockade had reduced plasma levels of NE as measured on day 8 compared with the placebo group [median (interquartile range): 962 pg/mL (508–1471) in the propranolol group vs 714 (391–1257)]. Additionally, mortality was lower in the intervention group [5/21 (23.81%) in the propranolol group vs 8/26 (30.77%) in the placebo].

Several other cohorts reported the association between the use of β-blocker and mortality (Table 3). Interestingly, most of the cohorts that evaluated the impact of β-blockage showed lower adjusted odds of mortality. These studies were combined in different manners in three meta-analyses. The first meta-analysis by Alali et al. included the randomized trial described above plus 8 cohorts. The 8 retrospective cohorts contained n = 4,782...
### Table 3: Systematic review

| Study       | Patient population | Design                                                                 | Intervention                                                                 | Outcomes                                                                 |
|-------------|--------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Ley et al.  | 2,252 patients     | Prospective multicenter observational study                           | Any β-blocker                                                               | β-blockers were associated with lower mortality (AOR 0.35; p < 0.001)     |
|             |                    |                                                                        |                                                                              | Propranolol was superior to other β-blockers (AOR 0.51, p = 0.010)        |
| Patel et al.| 49.7% received β- | 15 trauma centers in North America                                    | No protocol described                                                       | Reduction in plasma NE level as measured on day 8, median               |
|             | blocker            |                                                                        | Propranolol (1 mg intravenously every 6 hours for 7 days) + clonidine (0.1 mg | (inter-quartile range): 962 pg/mL (508–1471) in the propranolol group vs |
|             | 2,252 patients     |                                                                        | per tube every 12 hours for 7 days); within 48 hours post-injury             | 714 (391–1257)                                                         |
|             | Severe TBI patients|                                                                        |                                                                              | 21 patients in the β-blocker group                                       |
|             |                    |                                                                        |                                                                              | 26 patients in the control group                                         |
| Ahl et al.  | 362 patients with  | Retrospective, matched case control study from January 2007—December   | Any β-blocker                                                               | All-causes of mortality: intervention group [5/21 (23.81%)] vs [8/26    |
|             | severe TBI         | 2011                                                                   |                                                                              | (30.77%) in the placebo]                                                |
|             | 76 (21%) patients  |                                                                        |                                                                              |                                                                          |
|             | received β-blocker |                                                                        |                                                                              |                                                                          |
|             | 76 matched pairs   |                                                                        |                                                                              |                                                                          |
|             | were available for |                                                                        |                                                                              |                                                                          |
|             | analysis           |                                                                        |                                                                              |                                                                          |
| Ahl et al.  | 545 patients with  | Retrospective, matched case control study from 2007–2011               | Any β-blocker                                                               |                                                                          |
|             | severe TBI         |                                                                        |                                                                              |                                                                          |
|             | 80 (15%) patients  |                                                                        |                                                                              |                                                                          |
|             | received β-blocker |                                                                        |                                                                              |                                                                          |
|             | 80 matched pairs   |                                                                        |                                                                              |                                                                          |
|             | were analyzed after|                                                                        |                                                                              |                                                                          |
|             | propensity matching|                                                                        |                                                                              |                                                                          |
| Edavettal et| 214 admissions     | Retrospective, 2 years                                                | Any β-blocker                                                               |                                                                          |
|             |                    |                                                                        |                                                                              |                                                                          |
|             | 112 (52%) had no  |                                                                        |                                                                              |                                                                          |
|             | β-blocker use 46   |                                                                        |                                                                              |                                                                          |
|             | (21%) were on pre-|                                                                        |                                                                              |                                                                          |
|             | injury β-blocker   |                                                                        |                                                                              |                                                                          |
|             | 94 (44%) were on   |                                                                        |                                                                              |                                                                          |
|             | post-injury β-blocker |                                                              |                                                                              |                                                                          |
| Murry et al.| 28 moderate-to-    | Prospective interventional, non-randomized study March 2010–August      | Propranolol 1 mg intravenously every 6 hours starting within 12 hours of ICU | Mortality rates were (10% vs 10.7%, p = 0.9), propranolol vs control     |
|             | severe TBI         | 2013                                                                   | admission for a minimum of 48 hours                                         | group, respectively                                                     |

Contd...
| Study | Patient population | Design | Intervention | Outcomes |
|-------|--------------------|--------|--------------|----------|
| Zangbar et al.54 | 356 severe blunt TBI patients | Retrospective single level I trauma center from 2007–2013 | Any β-blocker | Metoprolol group displayed higher survival rates (78% vs 68%; \( p = 0.04 \)) |
| Ko et al.55 | 440 patients with moderate-to-severe TBI | Retrospective analysis of a prospective database from a single Level I trauma center from January 1, 2013–May 31, 2015 | Propranolol 1 mg IV every 6 hours started within 24 hour of admission | Propranolol started within 24 hour of admission was independently associated with lower mortality (AOR 0.25, \( p = 0.012 \)) |
| Mohseni et al.56 | 874 isolated severe TBI patients | Retrospective single academic trauma center from January 2007–December 2011 | Any β-blocker | No exposure to β-blockers was associated with a 5-fold increased risk of in-hospital mortality (AOR 5.0, CI 95% 2.7–8.5, \( p = 0.001 \)), regardless the type of β-blocker used |
| Schroepel et al.58 | 1,755 TBI patients | Retrospective single level I trauma center January 2008–December 2011 | Any β-blocker | Lower mortality in the propranolol group (3% vs 15%, \( p = 0.002 \)) |
| Mohseni et al.57 | 662 isolated severe TBI | Retrospective, 5 years | Any β-blocker | Patients exposed to β-blocker vs no β-blocker experienced 13% and 22% mortality, respectively (\( p = 0.01 \)), but β-blocker had a higher rate of infectious complications (30% vs 19%, \( p = 0.04 \)) |
| Bukur et al.58 | 2,446 isolated TBI | Retrospective single academic level I trauma center from between July 1998–December 2009 | Any β-blocker | Only Asian and Hispanic descent revealed significantly improved outcomes with β-blockers used |

Contd...
| Study                        | Patient population                                      | Design                                           | Intervention                                      | Outcomes                                                                                       |
|-----------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------------------------------|
| Schroepel et al.²⁹           | Whites (21%), 36% were on β-blocker                    | Retrospective single level I trauma center was from June 2003–December 2007 | Any β-blocker                                     | Mortality reduction of 65% by the use of a β-blocker (odds ratio, 0.347; confidence interval, 0.246–0.490) |
|                             | Asians (11%), 35% were on β-blocker                    |                                                  |                                                  |                                                                                                |
|                             | African Americans (8%), 34% were on β-blocker          |                                                  |                                                  |                                                                                                |
|                             | 2,601 blunt TBI patients                                |                                                  |                                                  |                                                                                                |
|                             | 506 (20%) received a β-blocker                         |                                                  | No protocol                                      |                                                                                                |
|                             | 2095 (80%) did not received any β-blocker              |                                                  |                                                  |                                                                                                |
| Salim et al.¹⁸               | 420 severe blunt TBI patients who had serial serum troponin (TnI) test | Retrospective single level I trauma center from January 1998–December 2005 | Any β-blocker                                     | β-Blocker was associated with lower mortality in TBI patients with TnI elevation (OR: 0.38; 95% CI: 0.15, 0.87, p = 0.03) |
|                             | 125 (29.8%) had TnI elevation on admission              |                                                  | No protocol                                      |                                                                                                |
|                             | 91 (21.7%) patients received a β-blocker               |                                                  |                                                  |                                                                                                |
|                             | 22 (5%) patients with elevated TnI received a β-blocker|                                                  |                                                  |                                                                                                |
| Inaba et al.⁶⁰               | 1,156 patients with isolated head injury               | Retrospective from July                         | Any β-blocker                                     | Adjusted odds ratio for mortality = 0.54; 95% CI, 0.33–0.91; p = 0.01. Elderly patients (55 years or older) with severe head injury (abbreviated injury score ≥ 4) had a mortality of 28% (β-blocker group) vs 60% (control group) |
|                             | 203 (18%) received β-blocker                           | 1998–December 2005                               | No protocol                                      |                                                                                                |
|                             | 953 (82%) did not receive β-blocker                    |                                                  |                                                  |                                                                                                |
| Cotton et al.⁶¹              | 420 patients with severe TBI                           | Retrospective from January 2004–March 2005       | Any β-blocker received for 2 or more consecutive days | Mortality in the β-blocker was 5.1% vs 10.8% in the control group (p = 0.036)                  |
|                             | 174 (42%) patients received β-blocker                  |                                                  |                                                  | Adjusted incidence rate ratio of mortality for β-blocker exposure = 0.29 (95% CI)              |
|                             | 246 (58%) patients did not receive β-blocker           |                                                  |                                                  |                                                                                                |
|                             | Patients with length of stay <4 or >30 days were excluded|                                                  |                                                  |                                                                                                |
| Riordan et al.⁶⁵             | 446 severe TBI patients                                | Retrospective, from December 2000–October 2005   | Any β-blocker                                     | β-Blocker exposure was associated with improved survival, especially to early β-blocker exposure and patients with cardiac uncoupling (percent of time that 5-minute heart rate standard deviation was between 0.3 bpm and 0.6 bpm on post-injury day 1) |

Contd...
patients and “demonstrated that exposure to β-blockers after TBI was associated with a reduction in the adjusted odds of in-hospital mortality by 65% (pooled adjusted odds ratio 0.35; 95% CI 0.27–0.45).” The same author updated this meta-analysis, which included one additional cohort. The authors found that the “exposure to β-blockers after TBI was associated with a reduction in in-hospital mortality (pooled OR 0.39, 95% CI: 0.27–0.56; \( P = 0.01 \))”. Finally, Chen et al. performed a systematic review and meta-analysis that included 13 cohorts with a total of 15,734 cases. Once again β-blocker use was associated with reduced odds of in-hospital mortality (OR 0.33; 95% CI 0.27–0.40; \( P < 0.001 \)). This is the only study that describes the association between β-blocker use and functional outcome after TBI.

The same group of authors describes the association between β-blocker use and the development of posttraumatic depression. Eighty patients received β-blocker and were matched with 80 pairs by propensity matching. Twenty-six patients (33%) in the non β-blocker group developed posttraumatic depression vs only 14 (18%) in the β-blocker group (\( p = 0.04 \)). Also, preadmission β-blocker use was associated with a reduced risk of depression.

### Association between β-blocker Use and Functional Outcome

One matched case–control study described the association of β-blocker and functional outcome. Ahl et al. were the first to study the association between the use of β-blockers and the long-term functional outcome, including the development of posttraumatic depression. In a retrospective-matched case–control study, the authors included 76 TBI patients who received a β-blocker started within 48 hours of hospital admission and continued until discharge. The cases were matched with 76 pairs using the propensity score. The risk of unfavorable long-term functional outcome, defined as a Glasgow outcome scale \( \leq 3 \), was more than two-fold in the control group (OR 2.44, 95% CI 1.01–6.03, \( p = 0.03 \)). Also, β-blocker cases had a shorter length of hospital stay (18.0 vs 26.8 days, \( p < 0.01 \)). This is the only study that describes the association between β-blocker use and functional outcome after TBI.

Other proposed mechanism of brain injury due to sympathoadrenal activation is the increase in the hydrostatic capillary pressure, which leads to the transcapillary fluid extravasation and the formation of interstitial cerebral edema. Medical therapy to control elevated intracranial pressure include (1) tracheal intubation with ventilation to achieve normocapnia, (2) sedation + analgesia to achieve a calm/motionless state, (3) cerebrospinal fluid drainage through an external ventricular drain, (4) hyperosmolar therapy (i.e., mannitol or hypertonic saline), and, (5) finally, the rescue therapies such as hyperventilation to induce hypocapnia, induced hypothermia, decompressive craniectomy, and metabolic suppression with barbiturate-induced coma.
However, all those described therapies are associated with adverse effects. Additionally, promising rescue interventions such as induced hypothermia and decompressive craniectomy did not result in outcomes better than medical therapy alone. Actually, in the RESCUEicp Trial, decompressive craniectomy was associated with higher rates of unfavorable functional outcome than medical therapy.

Because medical therapy to control intracranial pressure is associated with adverse effects and may impact negatively outcome, Asgeirsson et al. developed a clinical protocol to prevent/treat traumatic brain edema based on the theory that hydrostatic capillary pressure and colloid osmotic pressure are fundamentally involved in transcapillary fluid extravasation and the formation of interstitial cerebral edema. Hydrostatic capillary pressure was decreased by the use of an α2 agonist and a β1 -blocker (i.e., clonidine and metoprolol, respectively). Additionally, the authors added dihydroergotamine as a pre-capillary vasoconstrictor to reduce even further the hydrostatic capillary pressure, and also to reduce intracranial blood volume. Out of 11 comatose patients with predicted unfavorable functional outcome, 2 died (18%), while 9 patients (82%) survived with good recovery or moderate disability. This was one of the first descriptions of the use of β-blocker in the management of severe TBI, with promising results.

**DOES THE TYPE OF β-BLOCKER MATTER?**

The pharmacokinetic and pharmacodynamics of each specific β-blockers, especially regarding their ability to cross the BBB, should be taken into consideration when choosing the appropriate agent. For example, propranolol is a nonselective β-blocker that crosses the BBB, with enteral and intravenous formulation. Interestingly, Schroeppe10 in a retrospective cohort study found that patients who received β-blockers had a higher mortality rates (13% vs 6%, p < 0.001); however, mortality was lower in patients who received propranolol (3% vs 15%, p = 0.002). These results have been replicated by Ley et al., who showed in a prospective multicenter observational study in 15 trauma centers in North America that propranolol might be superior to other beta blockers.

Unfortunately, most of the cohort studies described in Table 2 did not have a specific protocol regarding the type or dose of β-blocker. Some exception needs to be commented: (1) the dose, moment of treatment initiation, and duration). High catecholamine levels after TBI is associated with worse outcome, and the use of β-blocker may reduce mortality and improve long-term outcome; however, these benefits must be adequately evaluated in a large multicenter clinical trial. Additionally, cardiac biomarkers may be used to stratify patients at higher risk that may benefit more by the use of β-blockers.

**REFERENCES**

1. Rizoli SB, Baja BNR, et al. Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study. Critical Care 2017;21(1):1–10. DOI: 10.1186/s13054-017-1620-1626.

2. Woolf PD, Hamill RW, et al. The predictive value of catecholamines in assessing outcome in traumatic brain injury. J Neurosurg 1987;66(6):875–882. DOI: 10.3171/jns.1987.66.6.0875.

3. Chesnut RM, Marshall SB, et al. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank. Acta Neurochir Suppl (Wien) 1993;59:121–125.

4. Berry C, Ley EJ, et al. Redefining hypotension in traumatic brain injury. Injury 2012;43(11):1833–1837. DOI: 10.1016/j.injury.2011.08.014.

5. Carney N, Totten AM, et al. Guidelines for the Management of Severe Traumatic Brain Injury. Neurosurgery 2017 Jan 1;80(1):6–15. DOI: 10.1227/NEU.0000000000001432.

6. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007;24(Suppl. 1):S1–S106. DOI: 10.1089/neu.2007.9999.

7. Brenner M, Stein DM, et al. Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury. J Trauma 2012;72(5):1135–1139. DOI: 10.1097/TA.0b013e3182fa9090.

8. Murray GD, Butcher I, et al. Multivariable Prognostic Analysis in Traumatic Brain Injury: Results from the IMPACT Study. J Neurotrauma 2007;24(2):329–337. DOI: 10.1089/neu.2006.0035.

9. Spaite DW, Hu C, et al. Mortality and Prehospital Blood Pressure in Patients With Major Traumatic Brain Injury. JAMA Surg December 2016; 1–9. DOI: 10.1001/jamasurg.2016.4686.

10. Dunser MW, Ruokonen E, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009;13(6):R181–R181. DOI: 10.1186/cc8167.

11. Herndon DN, Hart DW, et al. Reversal of Catabolism by Beta-Blockade after Severe Burns. N Engl J Med 2001;345(17):1223–1229. DOI: 10.1056/NEJMoa010342.

12. Diaz EC, Herndon DN, et al. Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns. Burns 2015;41(4):649–657. DOI: 10.1016/j.burns.2014.10.010.

13. Hammerle AF, Hackl JM, et al. The activity of the sympathetic nervous system following severe head injury. Intensive Care Med 2000;26(3):169. DOI: 10.1007/s001340051757299.

14. McLeod AA, Neil-Dwyer G, et al. Cardiac sequelae of acute head injury. Br Heart J 1982;47(3):221–226. DOI: 10.1136/hrt.47.3.221.

15. Larremore T, Markovich V. Cardiac sequelae of acute head injury. Br Heart J 1983;49(1):101–102. DOI: 10.1136/hrt.49.1.101.

16. Zygun DA, Kortbeek JB, et al. Non-neurologic organ dysfunction in severe traumatic brain injury*. Crit Care Med 2005;33(3):654–660. DOI: 10.1097/01.CCM.0000155911.01844.54.

17. Zygun D. Non-neurologic organ dysfunction in neurocritical care: impact on outcome and etiological considerations. Curr Opin Crit Care 2005;11(2):139–143. DOI: 10.1097/01.ccr.0000155356.86241.c0.

18. Clifton GL, Ziegler MG, et al. Circulating catecholamines and sympathetic activity after head injury. Neurosurgery 1981;8(1):10–14. DOI: 10.1227/00006123-198101000-00003.

19. Salim A, Hadjizacharia P, et al. Significance of Troponin Elevation After Severe Traumatic Brain Injury. J Trauma 2008;64(1):46–52. DOI: 10.1097/TA.0b013e31815eb15a.

**CONCLUSION**

Catecholamine surge after TBI is common and β-blockage has shown promising results. There is an important signal from several meta-analysis showing a significant reduction in mortality by the use of β-blocker after TBI. However, important uncertainty remains in the field, which needs to be answered, such as the best type (e.g., selective vs nonselective) and the regimen of β-blocker to be used (i.e., dose, moment of treatment initiation, and duration). High catecholamine levels after TBI is associated with worse outcome, and the use of β-blocker may reduce mortality and improve long-term outcome; however, these benefits must be adequately evaluated in a large multicenter clinical trial. Additionally, cardiac biomarkers may be used to stratify patients at higher risk that may benefit more by the use of β-blockers.
20. Martin M, Mullenix P, et al. Troponin Increases in the Critically Injured Patient: Mechanical Trauma or Physiologic Stress? J Trauma November 2005; 1086–1091. DOI: 10.1097/01.ta.0000190249.19668.37.

21. El-Menayr A, Asim M, et al. Predictive value of positive high-sensitivity troponin T in intubated traumatic brain injury patients. J Neurosurg 2017;129(6):1541–1549. DOI: 10.3171/2017.7.JNS17675.

22. Akashi YJ, Goldstein DS, et al. Takotsubo Cardiomyopathy. Circulation 2008;118(25):2754–2762. DOI: 10.1161/CIRCULATIONAHA.108.767012.

23. Smith WS, Matthay MA. Evidence for a hydrostatic mechanism in human neurogenic pulmonary edema. Chest 1997;111(5):1326–1333. DOI: 10.1378/chest.111.5.1326.

24. Di Battista AP, Rhind SG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic response after traumatic brain injury. J Trauma Acute Care Surg 2012;73(1):33–40. DOI: 10.1097/TA.0b013e31825769b.

25. Davidson JT, Charuzi I. Epinephrine-induced changes in the pulmonary pressure-volume curve of the intact and hypovolemic rabbit. Chest 1973;63(2):250–253. DOI: 10.1378/chest.63.2.250.

26. Ducker TB, Simmons RL. Increased intracranial pressure and pulmonary edema. 2. The hemodynamic response of dogs and monkeys to increased intracranial pressure. J Neurosurg 1968;28(2):118–123. DOI: 10.3171/jns.1968.28.2.0118.

27. Ley EJ, Clond MA, et al. β-Adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury. J Trauma Acute Care Surg 2012;73(1):1–14. DOI: 10.1097/TA.0b013e31820cda45.

28. Bell MJ, Kochanek PM, et al. Comparison of the interleukin-6 and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial. Trials 2012;13(1):177. DOI: 10.1186/1745-6215-13-177.

29. Alali AS, McCredie VA, et al. Beta blockers for acute traumatic brain injury: a systematic review and meta-analysis. Neurocrit Care 2014;20(3):514–523. DOI: 10.1007/s12028-013-9903-5.

30. Alali AS, Mukherjee K, et al. Beta-blockers and Traumatic Brain Injury. Annals of Surgery 2017;266(6):952–961. DOI: 10.1097/SLA.0000000000002286.

31. Chen Z, Tang L, et al. Therapeutic effect of beta-blocker in patients with traumatic brain injury: A systematic review and meta-analysis. Crit Care Med 2017;41(4):240–246. DOI: 10.1016/j.ccm.2017.05.035.

32. Ahl R, Thelin EP, et al. β-Blocker after severe traumatic brain injury is associated with better long-term functional outcome: a matched case control study. Eur J Trauma Emerg Surg 2017;43(6):783–789. DOI: 10.1007/s00068-017-0779-5.

33. Ahl R, Sjolin G, et al. Does early beta-blockade in isolated severe traumatic brain injury reduce the risk of post traumatic depression? Injury 2017;48(1):101–105. DOI: 10.1016/j.injury.2016.10.041.

34. Ahl R, Barmparas G, et al. Does Beta-Blockade Reduce the Risk of Depression in Patients with Isolated Severe Extracranial Injuries? World J Surg 2017;41(7):1801–1806. DOI: 10.1007/s00268-017-3935-5.

35. Naredi S, Eden E, et al. A standardized neurosurgical neurointensive therapy directed toward vasogenic edema after severe traumatic brain injury: clinical results. Intensive Care Med 1998;24(5):446–451. DOI: 10.1007/s001340050594.

36. Stocchetti N, Maas AirR. Traumatic Intracranial Hypertension. N Engl J Med 2014;370(22):2121–2130. DOI: 10.1056/NEJMra1208708.

37. Muizelaar JP, Marmarou A, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991;75(5):731–739. DOI: 10.3171/jns.1991.75.5.0731.

38. Andrews PJD, Harris BA, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. N Engl J Med 2016;374(14):1385–1385. DOI: 10.1056/NEJMct1600339.

39. Hutchinson PJ, Kolas AG, et al. Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med 2016 Sep 22; 375(12):1119–1130. DOI: 10.1056/NEJMoal1605215.

40. Ageirsson B, Grände PO, et al. A new therapy of post-trauma brain oedema based on haemodynamic principles for brain volume regulation. Intensive Care Med 1994;20(4):260–267. DOI: 10.1007/BF01708691.

41. Schroeppe1 TJ, Sharpe JP, et al. Traumatic brain injury and beta-blockers: not all drugs are created equal. J Trauma Acute Care Surg 2014;76(2):504–509, discussion509. 10.1097/TA.000000000000104.

42. Ley EJ, Leonard SD, et al. Beta blockers in critically ill patients with traumatic brain injury. J Trauma Acute Care Surg 2018;84(2):234–244. DOI: 10.1097/TA.0000000000001747.

43. Edavettal M, Gross BW, et al. An Analysis of Beta-Blocker Administration Pre-and Post-Traumatic Brain Injury with Subanalyses for Head Injury Severity and Myocardial Injury. Am Surg 2016;82(12): 1203–1208.

44. JS Murry, DM Hoang, et al. Prospective evaluation of early propranolol after traumatic brain injury. J Surg Res 2016;200(1):221–226. DOI: 10.1016/j.jss.2015.06.045.

45. B Zangbar, M Khalil, et al. Metoprolol improves survival in severe traumatic brain injury: clinical results. Intensive Care Med 1998;24(5):446–451. DOI: 10.1007/s001340050594.

46. Alali AS, McCredie VA, et al. Beta blockers for acute traumatic brain injury: a systematic review and meta-analysis. Neurocrit Care 2014;20(3):514–523. DOI: 10.1007/s12028-013-9903-5.

47. Alali AS, Mukherjee K, et al. Beta-blockers and Traumatic Brain Injury. Annals of Surgery 2017;266(6):952–961. DOI: 10.1097/SLA.0000000000002286.
61. Cotton BA, Snodgrass KB, et al. Beta-Blocker Exposure is Associated With Improved Survival After Severe Traumatic Brain Injury. J Trauma 2007;62(1):26–35. DOI: 10.1097/TA.0b013e31802d02d0.
62. Arbabi S, Campion EM, et al. Beta-Blocker Use is Associated With Improved Outcomes in Adult Trauma Patients. J Trauma 2007;62(1):56–62. DOI: 10.1097/TA.0b013e31802d972b.
63. Di Battista AP, Rhind SG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation 2016;13(1):1–14. DOI: 10.1186/s12974-016-0500-3.
64. Di Battista AP, Rizoli SB, et al. Sympathoadrenal Activation is Associated with Acute Traumatic Coagulopathy and Endotheliopathy in Isolated Brain Injury. Shock 2016;46:96–103. DOI: 10.1097/SHK.0000000000000642.
65. Riordan WP, Cotton BA, et al. Blocker Exposure in Patients With Severe Traumatic Brain Injury (TBI) and Cardiac Uncoupling. J Trauma 2007;63(3):503–510. DOI: 10.1097/TA.0b013e3181271c34.